^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Preferred regimens…Idelalisib + rituximab
